Davinder Gill On Researching Low-Cost Vaccines: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.
You may also be interested in...
In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.
MUMBAI - India's vaccines specialist Bharat Biotech is reshaping prices of life-saving vaccines with the announcement that it will make available its rotavirus vaccine at $1 per dose for government supplies once it clears Phase III trials. Bharat Biotech expects the product to be market-ready in the next three years
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.